Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients

Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients

Patients with visceral leishmaniasis (VL)–human immunodeficiency virus (HIV) coinfection experience increased drug toxicity and treatment failure rates compared to VL patients, with more frequent VL relapse and death. In the era of VL elimination strategies, HIV coinfection is progressively becoming...

Full description

Bibliographic Details
Main Authors: Wim Adriaensen, Thomas P. C. Dorlo, Guido Vanham, Luc Kestens, Paul M. Kaye, Johan van Griensven
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-01-01
Series:Frontiers in Immunology
Subjects:
visceral leishmaniasis
kala-azar
human immunodeficiency virus
immunotherapy
immunomodulation
coinfection
Online Access:http://journal.frontiersin.org/article/10.3389/fimmu.2017.01943/full

Internet

http://journal.frontiersin.org/article/10.3389/fimmu.2017.01943/full

Similar Items